(^18) WORLD NEWS l BIOSPECTRUM | SEPTEMBER 2018 | http://www.biospectrumindia.com
Glenmark Pharmaceuticals has
launched Akynzeo, a drug used
for prevention of chemotherapy-
induced nausea and vomiting, in
India and Nepal under an exclusive
licensing pact with Swiss pharma
group, Helsinn.
Akynzeo is an oral fixed
combination of netupitant 300
mg and palonosetron 0.5 mg. It is
administered in a single capsule
and offers 5-day prophylaxis from
of both acute and delayed phases of
chemotherapy-induced nausea and
vomiting (CINV).
The drug is already being
marketed in the EU, the US, and
several other leading markets
of the world. The product has
been developed by Helsinn, and
Glenmark has exclusive marketing
rights for it in India and Nepal.
Glenmark launches
Akynzeo in Nepal, India
Philips plans
further
expansion
in Pakistan
Royal Philips, a global
leader in health
technology, recently
announced its plans to
expand its products and
services for personal
health presence in the
Pakistan market. At
an event attended by
more than 300 local
business and retail
partners, Philips also
unveiled its ambitions
to improve the health
and well-being of
people in Pakistan
through its product
innovation. The
announcement follows
Pakistan’s social and
economic development
over the past decade
to become the world’s
24th largest economy
and predictions that it
will surpass Canada,
Australia and South
Korea, amongst others,
to be the 16th largest
by 2050. Philips’
expansion plans in
Pakistan follow its
successful global
transformation from
consumer electronics
giant to a world leader
in health technology
that improves the
health of populations
and enables better
outcomes at every
stage of along the
health continuum –
from healthy living
and prevention, to
diagnosis, treatment
and home care.
Sri Lanka to receive
healthcare funding from Japan
Sri Lanka will be getting a concessionary yen facility worth 15.5 billion rupees
from the government of Japan to boost specialist healthcare services for non-
communicable diseases (NCDs) at rural hospitals and upgrade technology at
biomedical and laboratory training facilities in the country. The government
is rolling out an initiative called
the ‘Health and Medical Service
Improvement Project’ to fight the
increasing trend of NCDs. The
Japanese government will fund the
project with a concessionary loan
of 10.63 billion yen (approx. 15.
billion rupees) through the Special
Terms for Economic Partnership
of the Japan International
Cooperation Agency. This project will expect to improve the diagnosis and
treatment of NCDs, especially cardiovascular diseases by improving the
medical facilities and equipment in tertiary hospitals in Anuradhapuura,
Kandy, Kurunegala, Badulla and Trincomalee. It will also upgrade technology
at the bio medical engineering services provided by the Health Ministry
and at medical laboratory training institutions. The project is scheduled for
completion by 2023.
singke
(singke)
#1